Twenty years of boosting antiretroviral agents: where are we today?

被引：11

作者：

Boffito, Marta ^{[1
,2
]}

Back, David ^{[3
]}

Gatell, Jose M. ^{[4
,5
,6
]}

机构：

[1] Chelsea & Westminster Hosp, St Stephens AIDS Trust, London SW10 9NH, England

[2] Univ London Imperial Coll Sci Technol & Med, London, England

[3] Univ Liverpool, Liverpool L69 3BX, Merseyside, England

[4] Hosp Clin Barcelona, IDIBAPS, Infect Dis Unit, Barcelona, Spain

[5] Hosp Clin Barcelona, IDIBAPS, AIDS Unit, Barcelona, Spain

[6] Univ Barcelona, Barcelona, Spain

来源：

AIDS | 2015年 / 29卷 / 17期

关键词：

boosted integrase inhibitors; boosted protease inhibitors; LOW-DOSE RITONAVIR; REVERSE-TRANSCRIPTASE INHIBITOR; TENOFOVIR DISOPROXIL FUMARATE; NAIVE HIV-1-INFECTED PATIENTS; CO-FORMULATED ELVITEGRAVIR; HIV-INFECTED PATIENTS; PROTEASE INHIBITOR; OPEN-LABEL; INITIAL TREATMENT; COFORMULATED ELVITEGRAVIR;

D O I：

10.1097/QAD.0000000000000800

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：2229 / 2233

页数：5

共 50 条

[1]

[Anonymous], 54 INT C ANT AG CHEM

[2]

[Anonymous], 12 INT WORKSH CLIN P

[3] Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial [J].

Arribas, Jose R. ;

Pialoux, Gilles ;

Gathe, Joseph ;

Di Perri, Giovanni ;

Reynes, Jacques ;

Tebas, Pablo ;

Thai Nguyen ;

Ebrahimi, Ramin ;

White, Kirsten ;

Piontkowsky, David .

LANCET INFECTIOUS DISEASES, 2014, 14 (07) :581-589

[4] A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction [J].

Baril, J. ;

Conway, B. ;

Giguere, P. ;

Ferko, N. ;

Hollmann, S. ;

Angel, J. B. .

HIV MEDICINE, 2014, 15 (05) :301-310

[5] New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents [J].

Boffito, Marta ;

Jackson, Akil ;

Owen, Andrew ;

Becker, Stephen .

DRUGS, 2014, 74 (01) :7-13

[6]

Boyd MA, 2013, LANCET, V381, P2091, DOI 10.1016/S0140-6736(13)61164-2

[7]

Cameron DW, 1999, AIDS, V13, P213, DOI 10.1097/00002030-199902040-00009

[8] Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells [J].

Cavet, ME ;

West, M ;

Simmons, NL .

BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (06) :1389-1396

[9] Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2:: a pooled subgroup analysis of data from two randomised trials [J].

Clotet, Bonaventura ;

Bellos, Nicholas ;

Molina, Jean-Michel ;

Cooper, David ;

Goffard, Jean-Chrostophe ;

Lazzarin, Adriano ;

Woehrmann, Andrej ;

Katlama, Christine ;

Wilkin, Timothy ;

Haubrich, Richard ;

Cohen, Calvin ;

Farthing, Charles ;

Jayaweera, Dushyantha ;

Markowitz, Martin ;

Ruane, Peter ;

Spinosa-Guzman, Sabrina ;

Lefebvre, Eric .

LANCET, 2007, 369 (9568) :1169-1178

[10] Impact of Different Low-Dose Ritonavir Regimens on Lipids, CD36, and Adipophilin Expression [J].

Collot-Teixeira, S. ;

De Lorenzo, F. ;

Waters, L. ;

Fletcher, C. ;

Back, D. ;

Mandalia, S. ;

Pozniak, A. ;

Yilmaz, S. ;

McGregor, J. L. ;

Gazzard, B. ;

Boffito, M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (04) :375-378

← 1 2 3 4 5 →